Elastrin Therapeutics is a UK and US-based biotech developing novel therapies to reverse cardiovascular disease. Its underlying technology was developed by Dr. Naren Vyavahare during the last 20 years at Clemson University, in collaboration with Dr. Charles Rice. Our team built a proprietary platform that targets and restores degraded elastin by removing the harmful calcification that stiffens arteries.
Company Details
- Employees
- 8
- Founded
- -
- Address
- Robert Robinson Avenue, John Eccles House,united States
- in****@****rin.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- elastrin.com
- HQ
- Oxford, England
Elastrin Therapeutics Questions
Elastrin Therapeutics's website is elastrin.com
Elastrin Therapeutics's LinkedIn profile is https://www.linkedin.com/company/elastrin
Elastrin Therapeutics has
8 employees.
View email and phone details for 8
employees at Elastrin Therapeutics.
Elastrin Therapeutics's industry is
Biotechnology Research
Elastrin Therapeutics's top competitors are
Clade,
Haya Therapeutics,
Autifony Therapeutics,
Cellbricks Therapeutics,
Cellestia Biotech,
Arecor Therapeutics,
Cyclarity Therapeutics,
Akari Therapeutics, Plc,
Samsara Therapeutics,
Endogena Therapeutics, Inc..
Elastrin Therapeutics's support email address is info@elastrin.com
Elastrin Therapeutics's categories are Biotechnology Research
Elastrin Therapeutics's founding year is 2017
